Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope
Antibodies have been raised against a synthetic peptide (IRDKIQKENALFRNL) containing a neutralizing epitope within the second variable region of the human immunodeficiency virus type 1 (HIV-1) SF2 strain external envelope glycoprotein (gp120) and also against equivalent peptides of the HIV-1 LAI, RF and MN isolates. The resulting antisera cross-react with heterologous peptides but binding to heterologous recombinant gp120 is more restricted. Antisera to HIV-1 SF2, RF and MN are able to neutralize homologous virus. Some cross-neutralization is also observed, but a consensus peptide failed to induce neutralizing antibodies to any of the isolates studied. Antibodies to the V2 and V3 epitopes give a higher neutralization index when acting together than when the individual sera are used alone. Antibodies induced in natural infection bind to two sets of hexamers within the region encompassed by the 15-mer peptide, and the response to these can differ between infected individuals and within the same host over time.
BermanP. W.,
GregoryT. J.,
RiddleL.,
NakamuraG. R.,
ChampeM. A.,
PorterJ. P.,
WurmF. M.,
HershbergR. D.,
CobbE. K.,
EichbergJ. W.1990; Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gpl60. Nature, London 345:622–625
Cheng-MayerC.,
LevyJ.1988; Distinct biological and serological properties of human immunodeficiency viruses from the brain. Annals of Neurology 23:S58–S61
Cheng-MayerC.,
HomsyJ.,
EvansL. A.,
LevyJ. A.1988; Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proceedings of the National Academy of Sciences, U.S.A 85:2815–2819
DavisD.,
ChaudhriB.,
StephensD. M.,
CarneC. A.,
WillersC.,
LachmannP. J.1990a; The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host’s previous exposure to similar epitopes on unrelated antigens. Journal of General Virology 71:1975–1983
DavisD.,
StephensD. M.,
WillersC.,
LachmannP. J.1990b; Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. Journal of General Virology 71:2889–2898
FungM. S. C.,
SunC. R. Y.,
GordonW. L.,
LiouR.-S.,
ChangT. W.,
SunW. N. C.,
DaarE. S.,
HoD. D.1992; Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. Journal of Virology 66:848–856
GalloR. C.,
SalahuddinS. Z.,
PopovicM.,
ShearerG. M.,
KaplanM.,
HaynesB. F.,
PalkerT. J.,
RedfieldR.,
OleskeJ.,
SafaiB.,
WhiteG.,
FosterP.,
MarkhamP. D.1984; Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500–503
GillT. J.,
KunzH. W.,
FriedmanE.,
DotyP.1963; Studies on synthetic polypeptide antigens. VIII. The inhibition of the antibody-synthetic polypeptide reaction by amino acids, dipeptides, amines, alcohols, and dicarboxylic acids. Journal of Biological Chemistry 238:108–123
GirardM.,
KienyM.-P.,
PinterA.,
Barre-SinoussiF.,
NaraP.,
KolbeH.,
KusumiK.,
ChaputA.,
ReinhartT.,
MuchmoreE.,
RoncoJ.,
KacsorekM.,
GomardE.,
GluckmanJ. C.,
FultzP. N.1991; Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proceedings of the National Academy of Sciences, U,. S,. A 88:542–546
HaigwoodN. L.,
BarkerC. B.,
HigginsW. K.,
SkilesP. V.,
MooreG. K.,
MannK. A.,
LeeD. R.,
EichbergJ. W.1990; Evidence for neutralizing antibodies directed against conformational epitopes of HIV-1 gp120. In Vaccines90 pp 313–320 Edited by
BrownF.,
ChanockR. M.,
GinsbergH.,
LernerR. A.
New York: Cold Spring Harbor Laboratory;
HaradaS.,
KobayashiN.,
KoyanagiY.,
YamamotoN.1987; Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-IIIB, LAV, and ARV). Virology 158:447–151
HoD. D.,
SchooleyR. T.,
RotaT. R.,
KaplanJ. C.,
FlynnT.,
SalahuddinS. Z.,
GondaM. A.,
HirschM. C.1984; HTLV-III in the semen and blood of a healthy homosexual man. Science 226:451–153
HoD. D.,
KaplanJ. C.,
RackauskasI. E.,
GurneyM. E.1988; Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239:1021–1023
HolmbergS. D.,
HorsburghC. R.,
WardJ. W.,
JaffeH. W.1989; . Biologic factors in the sexual transmission of human immunodeficiency virus. Journal of Infectious Diseases 160:116–125
KriegerJ. N.,
CoombsR. W.,
CollierA. C.,
RossS. O.,
ChalpoukaK.,
CummingsD. K.,
MurphyV. L.,
CoreyL.1991; Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral therapy. Journal of Infectious Diseases 163:386–388
LeonardC. K.,
SpellmanM. W.,
RiddleL.,
HarrisR. J.,
ThomasJ. N.,
GregoryT. J.1990; Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. Journal of Biological Chemistry 265:10373–10382
LevyJ. A.,
HoffmanA. D.,
KramerS. M.,
LandisJ. A.,
ShimabukuroJ. M.,
OshiroL. S.1984; Isolation of lympho-cytopathic retroviruses from San Francisco patients with AIDS. Science 225:840–842
LevyJ. A.,
KaminskyL. S.,
MorrowW. J. W.,
SteimerK.,
LuciwP.,
DinaD.,
HoxieJ.,
OshiroL.1986; Infection by the retrovirus associated with the acquired immunodeficiency syndrome. Clinical, biological, and molecular features. Annals of Internal Medicine 103:694–699
McKeatingJ. A.,
McKnightA.,
MooreJ. P.1991; Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. Journal of Virology 65:852–860
MannD. L.,
O’BrienS. J.,
GilbertD. A.,
ReidY.,
PopovicM.,
Read-ConnoleE.,
GalloR. C.,
GazdarA. F.1989; Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Research and Human Retroviruses 5:253–255
NeurathA. R.,
StrickN.,
LeeE. S. Y.1990; B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides. Journal of General Virology 71:85–95
PopovicM.,
SarnagadharanM. G.,
ReadE.,
GalloR. C.1984; Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and preAIDS. Science 224:497–500
RatnerL.,
HaseltineW.,
PatarcaR.,
LivakK. J.,
StarcichB.,
JosephsS. F.,
DoranE. R.,
RafalskiA.,
WhitehornE. A.,
BaumeisterK.,
IvanoffL.,
PettewayS. R.,
PearsonM. L.,
LautenburgerJ. A.,
PapasT. S.,
GhrayebJ.,
ChangN. T.,
GalloR. C.,
Wong-StaalF.1985; Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature, London 313:277–284
Sanchez-PescadorR.,
PowerM. D.,
BarrB. J.,
SteimerK. S.,
StempienM. M.,
Brown-ShimmerS. L.,
GeeW. W.,
RenardA.,
RandolphA.,
LevyJ. A.,
DinaD.,
LuciwP. A.1985; Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227:484–492
SpenceR. P.,
JarvillW. M.,
FernsR. B.,
TedderR. S.,
ParkerD.1989; The cloning and expression in Escherichia coli of sequences coding for p24, the core protein of human immunodeficiency virus, and the use of the recombinant protein in characterizing a panel of monoclonal antibodies against the viral p24 protein. Journal of General Virology 70:2843–2851
SteimerK. S.,
van NestG. A.,
HaigwoodN. L.,
TillsonE. M.,
George-NascimentoC.,
BarrP. J.,
DinaD.1988; Recombinant env and gag polypeptides in characterizing HIV-1-neutralizing antibodies. In Vaccines88 pp 347–355 Edited by
GinsbergH.,
BrownF.,
LernerR. A.,
ChanockR. M.
New York: Cold Spring Harbor Laboratory;
StephensD. M.,
EichbergJ. W.,
HaigwoodN. L.,
SteimerK. S.,
DavisD.,
LachmannP. J.1992; Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. Journal of General Virology 73:1099–1106
ThaliM.,
FurmanC.,
WahrenB.,
PosnerM.,
HoD. D.,
RobinsonJ.,
SodroskiJ.1992; Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. Journal of Acquired Immune Deficiency Syndromes 5:591–599
TilleyS. A.,
HonnenW. J.,
RachoM. E.,
ChouT.-C.,
PinterA.1992; Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD-4 binding site of gp120. AIDS Research and Human Retroviruses 8:461–467
TisdaleM.,
ErtlP.,
LarderB. A.,
PurifoyD. J. M.,
DarbyG.,
PowellK. L.1988; Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function. Journal of Virology 62:3662–3667
VogtM. W.,
WittD. J.,
CravenD. E.,
ByingtonR.,
CrawfordD. F.,
SchooleyR. T.,
HirschM. S.1986; Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet i:525–527
WeissR. A.,
ClaphamP. R.,
WeberJ. N.,
DalgleishA. G.,
LaskyL. A.,
BermanP. W.1986; Variable and conserved neutralization antigens of human immunodeficiency virus. Nature, London 324:572–575
WofsyC. B.,
CohenJ. B.,
HauerL. B.,
PadianN. S.,
MichaelisA. A.,
EvansL. A.,
LevyJ. A.1986; Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet i:527–529
ZaguryD.,
BernardJ.,
LiebowitchJ.,
SafaiB.,
GroopmanJ. E.,
FeldmanM.,
SarngadharanM. G.,
GalloR. C.1984; HTLV-III in cell cultures from the semen of two patients with AIDS. Science 226:449–451
Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope